Edoxaban Safety and Effectiveness in Real-Life Patients with Heart Failure and Atrial Fibrillation: EMAYIC Study.

ABSTRACT: Background/Objectives: Real-world data about clinical characteristics and edoxaban performance in patients with heart failure (HF) and atrial fibrillation (AF) are lacking. The EMAYIC study aimed to assess and compare the profile and cardiovascular outcomes in those patients according to HF subtypes based on left ventricular ejection fraction (LVEF). Methods: Multicentre, prospective (follow-up: 12 months), observational study. Consecutive adult patients were included at cardiology and internal medicine clinics across Spain with HF (NT-proBNP > 600 pg/mL) and AF, receiving edoxaban as per routine clinical practice. Incidence of major or clinically relevant non-major (CRNM) bleeding and composite of incidence of stroke or systemic embolism (SE) were assessed according to HF su

SUBMITTER: Salguero-Bodes R 

PROVIDER: S-EPMC12565050 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature